This axis correlates with poor prognosis, and targeting YAP/TAZ-EZH2-MYC restored PTEN expression and reduced tumor growth, suggesting a novel therapeutic avenue (Lo Sardo et al., 2024[80]). This evidence concerns the gene YAP1 and neoplasm.